|
February 26, 2024
|
Biora Therapeutics Announces Successful Completion of Single-Ascending Dose (SAD) Cohorts of Phase 1 Clinical Study of BT-600
|
|
February 8, 2024
|
Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium
|
|
January 22, 2024
|
Biora Therapeutics Announces Participation in Fireside Chat Hosted by H.C. Wainwright & Co.
|
|
January 16, 2024
|
Biora Therapeutics Provides Outlook for 2024
|
|
January 8, 2024
|
Biora Therapeutics Announces Initiation of Phase 1 Clinical Study of BT-600
|
|
January 2, 2024
|
Biora Therapeutics Progresses Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
|
|
December 19, 2023
|
Biora Therapeutics Announces New Patent for its NaviCap™ Targeted Oral Delivery Platform
|
|
December 18, 2023
|
Biora Therapeutics Accelerates Debt Reduction and Raises Capital with Large Institutional Investors
|
|
December 11, 2023
|
Biora Therapeutics Announces New Research Collaboration for the BioJet™ Systemic Oral Delivery Platform
|
|
November 30, 2023
|
Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
|